Oral rifampicin in cases of cutaneous leishmaniasis with multiple lesions (a pilot study).
Indian J Dermatol Venereol Leprol
;
2002 Sep-Oct; 68(5): 272
Article
in English
| IMSEAR
| ID: sea-52325
ABSTRACT
The multiple lesions of cutaneous leishmaniasis (CL) require an effective oral agent. We are reporting a pilot study of oral rifampicin 600 mg. bid or 20 mg/kg. body weight in cases of CL with multiple lesions. Our study shows 83.3% parasitological and clinical cure with insignificant side effects after 4 weeks of therapy. No relapse upto 6 months of completion of study was seen.
Full text:
Available
Index:
IMSEAR (South-East Asia)
Language:
English
Journal:
Indian J Dermatol Venereol Leprol
Year:
2002
Type:
Article
Similar
MEDLINE
...
LILACS
LIS